The company is paying $350 million upfront, and potentially $1.2 billion overall, for a radiopharmaceutical for prostate ...

Instead of homing in on PSMA—currently the most validated target in prostate cancer—BMS and Philochem will instead ...

FN Media Group News Commentary - The global oncology market is undergoing rapid growth, mainly due to the increasing number of cancer cases around the world. The World Health Organization estimates ...

BMS kickstarted its radiopharma drive last year when it completed a $4.1 billion acquisition of San Diego-based RayzeBio, ...

BMS entered the radiopharma space via its $4.1 billion buyout of RayzeBio at the end of 2023. Unlike Novartis’ approved ...

This gives us both state-of-the-art diagnostic capabilities for prostate cancer and gives us state-of-the art treatments for ...

Cancer cannot be understood as a single, uniform disease. The more we delve into studying each type of tumor, the more we ...

Patients with metastatic castration-sensitive prostate cancer (mCSPC), who have specific genetic mutations, were found to ...

The first trial of adjuvant platinum-based chemotherapy plus paclitaxel in patients with high-risk penile cancer provided some insights.

As a leader in its category, Sinotau is probably hoping to follow in the footsteps of Hengrui Pharmaceuticals (1276.HK; ...